In April 2024, RedHawk Ventures allocated $25,000 to Apricity Robotics’ priced Series Seed round at a $4.5M pre-money valuation. The round was led by institutional investor, Orlando Health.

Core components of the RedHawk Ventures investment thesis included applicable expertise of the management team (including extensive experience in Procter & Gamble’s robotics organization), founder-company fit, alignment with robotics macro trends in healthcare industry, and strength of lead investor.

Apricity Robotics’ is the developer of an AI-based echocardiogram robot, featuring an innovative approach that addresses the pressing challenges in the healthcare industry, particularly the shortage of sonographers and the need for efficient echocardiogram services. Apricity's robotic echo machine not only streamlines the process of performing echocardiograms but also opens up new possibilities with planned add-on functionalities such as DVT detection and Cardiothoracic imaging, making it a versatile and valuable tool for healthcare providers. With a pricing model that offers a quick return on investment for hospitals and a clear focus on mitigating risks through regulatory compliance and customer validations, Apricity Robotics is poised to capture a significant share of the rapidly growing medical robotics market.

Aaron Crookes
Co-Founder, Chief Executive Officer| Miami ‘16, Biomedical Engineering, Physics

Jeffrey Toaddy
Co-Founder, Chief Financial Officer | Miami ‘05, Business, Entrepreneurship